Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 788046 10.3389/fphar.2021.788046 Pharmacology Erratum Erratum: Design of a Proteolytically Stable Sodium-Calcium Exchanger 1 Activator Peptide for In Vivo Studies Frontiers Production Office Erratum: A Proteolytically Stable NCX1 Activator Frontiers Production Office * Frontiers Media SA, Lausanne, Switzerland

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: Frontiers Production Office, pharmacology.production.office@frontiersin.org

This article was submitted to Pharmacology of Ion Channels and Channelopathies, a section of the journal Frontiers in Pharmacology

 21 10 2021 2021 12 788046 01 10 2021 01 10 2021 Copyright © 2021 Frontiers Production Office. 2021 Frontiers Production Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 An Erratum onDesign of a Proteolytically Stable Sodium-Calcium Exchanger 1 Activator Peptide for In Vivo Studies by Wanichawan, P., Skogestad, J., Lunde, M., Støle, T. P., Stensland, M., Nyman, T. A., Sjaastad, I., Sejersted, O. M., Aronsen, J. M. and Carlson, C. R. (2021). Front. Pharmacol. 12:638646. doi:10.3389/fphar.2021.638646 PLM NCX1 disruptor peptide NKA cardiac brain peptide arrays peptidomimetics

Due to a production error, the incorrect Supplementary Material files were published. The Supplementary Material files have been corrected.

The publisher apologizes for this mistake. The original article has been updated.